Does lapatinib work against HER2-negative breast cancers?

Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journalComment/debatepeer-review

15 Scopus citations


Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.

Original languageEnglish (US)
Pages (from-to)1355-1357
Number of pages3
JournalClinical Cancer Research
Issue number5
StatePublished - Mar 1 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Does lapatinib work against HER2-negative breast cancers?'. Together they form a unique fingerprint.

Cite this